Regional Studies ACHIEVE-J (NCT06010004) evaluates orforglipron specifically in Japanese patients with type 2 diabetes, addressing potential population-specific differences in efficacy, safety, and dosing requirements that are important for regulatory submission in Japan
Research suggests that the medication, a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, originally developed to manage type 2 diabetes, may be able to treat a wide range of conditions involving impulse control, like binge eating disorder
At controlled room temperature (68-77 degrees Fahrenheit), one week of exposure is well within the stability window of most compounded semaglutide formulations
Semaglutide (Ozempic) helps regulate appetite by mimicking a hormone called GLP-1, which plays a key role in insulin regulation and hunger control
Still, many patients face steep costs and limited insurance coverage